Myeloproliferative Neoplasms

Ivosidenib Plus Venetoclax and Azacitidine Safe, Effective in IDH-Mutated Myeloid Malignancies

Treatment with ivosidenib plus venetoclax, with or without azacitidine, had an acceptable safety profile and led to high rates of complete responses in a...

Investigating Iptacopan Plus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria With Active Hemolysis

Adding iptacopan to the FDA-approved C5 inhibitor eculizumab led to hematologic benefits in patients with paroxysmal nocturnal hemoglobinuria and active hemolysis, according to results...
image of a busy hospital hallway with medical staff walking in different directions

Researchers Evaluate the Prognostic Importance of BCR-ABL Transcripts in Chronic Myeloid Leukemia

In a meta-analysis published in Leukemia Research, investigators reported that the e14a2 BCR-ABL1 transcript is the more common transcript type in patients with chronic...
image of a busy hospital hallway with medical staff walking in different directions

Comparing Long-Term Outcomes With Nilotinib or Imatinib in CML

Ten-year follow-up data from the ENESTnd study showed that nilotinib led to higher molecular response rates than imatinib in patients with newly diagnosed chronic-phase...
woman in white robe stands next to window and looks outside

Pegcetacoplan Outperforms Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

Treatment with pegcetacoplan led to greater improvements in hemoglobin level and levels of transfusion-independence, compared with the C5 inhibitor eculizumab, according to results from...
doctors holding files and discussing a patient

NFE2 Somatic Mutations Linked With AML Transformation in Patients With MPNs

In patients with myeloproliferative neoplasms (MPNs), presence of somatic mutations in the hematopoietic transcription factor NFE2 (nuclear factor erythroid 2) are associated with greater...
patient sits on couch lookin out window while loved one wraps her arm around her

Venetoclax Plus Azacitidine Leads to High Response Rates in CMML

Approximately two-thirds of patients with chronic myelomonocytic leukemia (CMML) responded to treatment with a combination of the BCL2 inhibitor venetoclax and the hypomethylating agent...
Advertisement

Journal Reading List

Advertisement
Advertisement